Short Interest in Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Rises By ∞

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 134,468 shares, a growth of ∞ from the July 30th total of 0 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 473,636 shares, the short-interest ratio is currently 0.3 days.

Insider Activity at Latigo Biotherapeutics

In related news, major shareholder Foresite Capital Management V, bought 140,000 shares of the stock in a transaction dated Monday, August 10th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James B. Tananbaum acquired 140,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the director directly owned 2,008,024 shares of the company’s stock, valued at approximately $36,144,432. This trade represents a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

Latigo Biotherapeutics Price Performance

Shares of NASDAQ LTGO traded down $0.77 during midday trading on Friday, reaching $24.23. 217,741 shares of the company were exchanged, compared to its average volume of 423,531. Latigo Biotherapeutics has a 1 year low of $17.22 and a 1 year high of $25.93.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Latigo Biotherapeutics to a “hold” rating in a research report on Saturday, August 15th.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.